Natera (NASDAQ:NTRA) Lifted to “Hold” at StockNews.com

StockNews.com upgraded shares of Natera (NASDAQ:NTRAFree Report) from a sell rating to a hold rating in a report issued on Friday morning.

Several other equities research analysts have also recently issued reports on the company. Raymond James cut Natera from a strong-buy rating to an outperform rating and raised their target price for the stock from $68.00 to $85.00 in a research note on Tuesday, February 20th. Piper Sandler boosted their price objective on shares of Natera from $110.00 to $120.00 and gave the company an overweight rating in a report on Tuesday, May 14th. TD Cowen increased their target price on shares of Natera from $123.00 to $137.00 and gave the stock a buy rating in a research note on Friday, May 10th. The Goldman Sachs Group lifted their price target on shares of Natera from $90.00 to $100.00 and gave the company a buy rating in a research report on Monday, April 15th. Finally, Craig Hallum began coverage on shares of Natera in a report on Monday, April 8th. They issued a buy rating and a $117.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $98.47.

Read Our Latest Analysis on NTRA

Natera Stock Down 1.9 %

Shares of NASDAQ:NTRA opened at $106.46 on Friday. Natera has a 52-week low of $36.90 and a 52-week high of $108.75. The company has a quick ratio of 3.96, a current ratio of 4.12 and a debt-to-equity ratio of 0.36. The business has a fifty day moving average of $93.96 and a two-hundred day moving average of $74.07. The stock has a market cap of $13.07 billion, a P/E ratio of -34.12 and a beta of 1.38.

Natera (NASDAQ:NTRAGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.16. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The firm had revenue of $367.70 million during the quarter, compared to analysts’ expectations of $316.31 million. During the same period last year, the business earned ($1.23) earnings per share. Natera’s revenue was up 52.1% compared to the same quarter last year. On average, research analysts expect that Natera will post -2.44 earnings per share for the current year.

Insider Activity

In related news, insider Jonathan Sheena sold 447 shares of the business’s stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $90.22, for a total transaction of $40,328.34. Following the completion of the transaction, the insider now directly owns 347,731 shares of the company’s stock, valued at approximately $31,372,290.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Natera news, insider Jonathan Sheena sold 447 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $90.22, for a total transaction of $40,328.34. Following the completion of the transaction, the insider now owns 347,731 shares in the company, valued at approximately $31,372,290.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Daniel Rabinowitz sold 20,526 shares of the firm’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $89.01, for a total transaction of $1,827,019.26. Following the completion of the sale, the insider now owns 204,218 shares in the company, valued at $18,177,444.18. The disclosure for this sale can be found here. Over the last three months, insiders have sold 323,628 shares of company stock worth $29,214,503. Corporate insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Comerica Bank lifted its stake in Natera by 458.0% during the first quarter. Comerica Bank now owns 14,866 shares of the medical research company’s stock worth $1,360,000 after purchasing an additional 12,202 shares during the last quarter. Castleark Management LLC purchased a new stake in shares of Natera during the 1st quarter worth approximately $6,826,000. Kennedy Capital Management LLC acquired a new position in shares of Natera in the 1st quarter valued at $292,000. Bayesian Capital Management LP grew its position in shares of Natera by 514.7% in the 1st quarter. Bayesian Capital Management LP now owns 34,300 shares of the medical research company’s stock valued at $3,137,000 after buying an additional 28,720 shares during the last quarter. Finally, Blue Water Life Science Advisors LP raised its stake in Natera by 26.6% during the 1st quarter. Blue Water Life Science Advisors LP now owns 503,094 shares of the medical research company’s stock worth $46,013,000 after acquiring an additional 105,658 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

About Natera

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Read More

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.